NCE-1 Intelligence & Market Opportunity

Revuforj

Revumenib Citrate

Anticancer

Oral Tablets

Revuforj is a drug used to treat relapsed or refractory acute leukemia. The treatment of acute leukemia is done with a lysine methyltransferase 2A gene translocation (KMT2A) in adults. This drug is also indicated for children 1 year and older whose disease has come back or has not improved after previous treatments.

Approval Date

15-Nov-24

NCE-1 Date

15-Nov-28

NCE Date

15-Nov-29

Commercial snapshot

Market performance & projections

Revenue ($M)

125

CAGR (%)

0.5416

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

261

2027

386

2028

555

2029

706

2030

863

2031

1027

2032

1188

Molecule profile

Details & specifications

Molecule

Revumenib Citrate

Innovator

SYNDAX PHARMACEUTICALS INC

Dosage Form

Oral Tablets

Strength

25 mg, 110 mg and 160 mg

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory acute leukemia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.